¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"high frequency deafness"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • high-tension pulse
    °í±äÀ可¹Ú
  • high-threshold cell
    °í¹®Åΰª¼¼Æ÷
  • angular frequency
    °¢Á֯ļö
  • critical flicker frequency
    ÀÓ°èÇø®Ä¿ºóµµ
  • critical fusion frequency
    ÀÓ°èÀ¶ÇÕºóµµ
  • cumulative frequency
    ´©Àûµµ¼ö
  • cutoff frequency
    Â÷´ÜÁ֯ļö
  • cyclic frequency
    ÁÖ±âÁ֯ļö
  • center frequency
    Áß½ÉÁ֯ļö
  • dual frequency
    ÀÌÁßÁÖÆÄ
  • discharge frequency
    1. ¹æÀüÁ֯ļö 2. ÈïºÐ¹ß»çºóµµ
  • frequency
    1. ºóµµ, µµ¼ö, ¼ö 2. Á֯ļö, Áøµ¿¼ö
  • frequency axis
    Á֯ļöÃà
  • frequency curve
    µµ¼ö°î¼±
  • frequency distribution
    µµ¼öºÐÆ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • high voltage radiography
    °íÀü¾ÐÃÔ¿µ¼ú
  • high-altitude illness
    °í¼ÒÁúº´
  • high-density lipoprotein
    °í¹ÐµµÁöÁú´Ü¹é
  • high-dose tolerance
    Ç׿ø°ú·®Çã¿ë
  • high-zone tolerance
    Ç׿ø°ú·®Çã¿ë
  • one step high level resistance
    ÀÏȸ°íÀúÇ×ȹµæ
  • angular frequency
    °¢Á֯ļö
  • frequency axis
    Á֯ļöÃà
  • center frequency
    Áß½ÉÁ֯ļö
  • critical flicker frequency
    ÀÓ°èÇø®Ä¿ºóµµ
  • critical fusion frequency
    ÀÓ°èÀ¶ÇÕºóµµ
  • cumulative frequency
    ´©Àûµ¾¼ö
  • cutoff frequency
    Â÷´ÜÁ֯ļö
  • cyclic frequency
    ÁÖ±âÁ֯ļö
  • frequency curve
    µµ¼ö°î¼±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • radio-frequency pulse
    °íÁÖÆÄ ÆÞ½º
  • radio-frequency pulse sequence
    °íÁÖÆÄ ÆÞ½º ¿¬¼â
  • radio-frequency thermal effect
    °íÁÖÆÄ ¿­ È¿°ú
  • recombination frequency
    ÀçÁ¶ÇÕºóµµ
  • reference frequency
    ±âÁØ Á֯ļö
  • relative frequency
    ºñ±³ºóµµ(ËÓË´Ë×̬).
  • HDL (High-density lipoproteins)
    °í¹ÐµµÁö´Ü¹éÁú(ÍÔÚËÓøò·Ó±ÛÜòõ)
  • High energy phosphate
    °í¿¡³ÊÁöÀλê
  • High intensity proton flow
    °í°­µµ ¾çÀÚ À¯µ¿
  • High-density lipoprotein = HDL
    °í¹ÐµµÁö´Ü¹éÁú(ÍÔÚËÓøò·Ó±ÛÜòõ)
  • High-molecular-weight kininogen
    °íºÐÀÚ·®Å°´Ï³ëÁø
  • High-threshold cells
    °í¿ªÄ¡¼¼Æ÷(ÍÔ ö·á¬øà)
  • high altitude
    °í¼Ò
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(ÍÔá¶àõîåúìϹñòÊ¥ñø) .
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(Ë­ËÛËÛËøÌ´Ë´Ì¡?Ì¡) .
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • tone deafness
    À½Ä¡, ½ÇÀ½¾ÇÁõ
  • total deafness
    (¿Ï)Àü³ó
  • toxic deafness
    Áßµ¶¼º³­Ã»
  • transmission deafness
    ÀüÀ½¼º³ó
  • unilateral deafness
    ÆíÃø³ó, ÀÏÃø³ó
  • unilateral deafness
    ÆíÃø³ó(ø¶ö°Öì), ÀÏÃø³ó
  • familial high density lipoprotein def
    °¡Á·¼º °íºñÁ߸®Æ÷´Ü¹éÁú°áÇÌ Áõ.
  • high altitude
    °í¼Ò
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(Ë­ËÛËÛËøÌ´Ë´Ì¡?Ì¡) .
  • high altitude polycyth(a)emia
    °í¼Ò¼º ÀûÇ÷±¸Áõ°¡(Áõ)(ÍÔá¶àõîåúìϹñòÊ¥ñø) .
  • high altitude pulmonary edema
    °íÁöÆóºÎÁ¾.
  • high caloric diet
    °íÄ®·Î¸®½ÄÀÌ.
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
  • high dizziness
    °í¼ÒÇö±âÁõ(Ë­ËÛ̴˻̡).
  • high dose rate
    °í¼±·®À²
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
HFR high-frequency recombination
Hft high-frequency transfer
HFV high-frequency ventilation
HiPRF high pulse repetition frequency
shf super-high frequency
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
CFF Critical Fusion Frequency
DFIC Dominant frequency instability coefficient
ELF Extremely Low Frequency
FRQ FREQUENCY
FFQ Food Frequency Questionnaire
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • high velocity signal loss
    °í¼Óµµ ½ÅÈ£ ¼Ò½Ç
  • high voltage radiography
    °í¾Ð ¹æ»ç¼± ÃÔ¿µ¼ú, °í¾Ð ÃÔ¿µ¼ú, °íÀü¾Ð ÃÔ¿µ¼ú
  • high-affinity agonist
    °íģȭ¼º ÀÛ¿ë ¹°Áú
  • high-density lipoprotein
    °í¹Ðµµ Áö¹æ ´Ü¹é
  • high-energy phosphate bond
    °í¿¡³ÊÁö ÀÎ»ê °áÇÕ
    ÀÌ °áÇÕÀº ¾Æµ¥³ë½Å »ïÀλê, Æ÷½ºÆ÷Å©·¹¾ÆÆ¾, ´ç´ë»çÀÇ Áß°£»ê¹° µî¿¡ Á¸ÀçÇÑ´Ù.
  • high-energy sulfer bond
    °í¿¡³ÊÁö À¯È² °áÇÕ
    ÀÌ °áÇÕ¿¡¼­ °¡Àå Áß¿äÇÑ °ÍÀº ¾Æ¼¼Æ¿ CoA¿¡ Á¸ÀçÇÏ´Â °ÍÀ¸·Î¼­ Áö¹æ»ê »ýÇÕ¼ºÀÇ ÁÖ¿ä ¿¡³ÊÁö¿øÀÌ µÈ´Ù.
  • high-power interaction
    °íÃâ·Â »óÈ£ ÀÛ¿ë
  • high-speed grinding
    °í¼Ó »èÁ¦
    ºü¸¥ ¼Óµµ·Î °¥¾Æ³»´Â °Í.
  • high-threshold class
    °í¿ªÄ¡±º
    ¿ªÄ¡ÀÇ Å©±â°¡ ³ôÀº Áý´Ü.
  • high-threshold mechanoreceptor
    °í¿ªÄ¡ ±â°è ¼ö¿ëü, °í¿ªÄ¡ ±â°è ¼ö¿ë±â
  • high-threshold neuron
    °í¿ªÄ¡ ´º¿ì·±
    ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â µ¥ Å« ÀÚ±ØÀÌ ÇÊ¿äÇÑ ´º¿ì·±.
  • high-voltage stimulation
    °íÀü¾Ð ÀÚ±Ø
    ³ôÀº Àü¾ÐÀÇ Àü±â ÀÚ±Ø.
  • paramagnetic high susceptibility
    »óÀÚ¼º °íÀÚÈ­À²
  • super high field MR scanner
    ÃʰíÀÚÀå MR ½ºÄ³³Ê, Ãʰí ÀÚÀå Àڱ⠰ø¸í ½ºÄ³³Ê
  • tolerance to high altitude
    °í¼Ò ³»¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
high blood pressure <cardiology> Persistently high arterial blood pressure. Hypertension may have no known cause (essential or idiopathic hypertension) or be associated with other primary diseases (secondary hypertension).
This condition is considered a risk factor for the development of heart disease, peripheral vascular disease, stroke and kidney disease.
(29 Sep 1997)
high blood triglyceride <biochemistry> Elevation of triglycerides, a fatty substance found in the bloodstream. Normal triglyceride blood levels should be 10-150 milligrams per decilitre. Elevations of the triglyceride level (particularly in association with elevated cholesterol) have been correlated with the development of atherosclerosis, the underlying cause of heart disease and stroke.
Origin: Gr. Haima = blood
(27 Sep 1997)
high-bred Bred in high life; of pure blood.
Source: Websters Dictionary
(01 Mar 1998)
high-calorie diet A diet containing upward of 4,000 calories per day.
(05 Mar 2000)
high convex The segment of a sphere of short radius.
(05 Mar 2000)
high density lipoprotein <biochemistry> These lipoproteins acts to carry cholesterol in the bloodstream.
Raised high density lipoprotein levels have been correlated with a lower risk for heart disease. Less than 35 mg/dl is considered a positive risk factor for coronary artery disease, over 60 mg/dl is considered a negative risk factor (reduces your risk of heart disease).
Recent studies show a low high density lipoprotein level is the strongest predictor of cardiovascular death in women.
Acronym: HDL
(18 Nov 1997)
high dose tolerance The induction of tolerance by exposure to high doses of antigen.
(05 Mar 2000)
high-egg-passage vaccine Living Flury strain rabies virus at the 180th to 190th level egg passage (embryonate eggs), used for vaccination of cattle and cats, low-egg-passage (LEP) vaccine: at the 40th to 50th passage level, containing 103 to 104 mouse LD50; nonpathogenic in dogs but retains some pathogenicity for cattle and cats.
(05 Mar 2000)
high endothelial postcapillary venules Venule's in the lymph nodes, tonsils, and Peyer's patches that have a high-walled endothelium through which blood lymphocytes migrate into the lymphatic parenchyma.
(05 Mar 2000)
high enema An enema instilled high up into the colon.
Synonym: enteroclysis.
(05 Mar 2000)
high energy bond <chemistry> Chemical bonds that release more than 25kJ/mol on hydrolysis: their importance is that the energy can be used to transfer the hydrolysed residue to another compound. The risk in using the term is that students may think the bond itself is different in some way, whereas it is the compound that matters. Hydrolysis of creatine phosphate yields 42.7kJ/mol, of phosphoenolpyruvate, 53.2, ATP to ADP, 30.5: the latter is important because it shows that energetically the hydrolysis of creatine phosphate will suffice to reconstitute ATP, hence the use of creatine phosphate in muscle.
(18 Nov 1997)
high energy compounds Classically, a group of phosphoric esters whose hydrolysis takes place with a standard free energy change of -5 to -15 kcal/mol (or, -20 to -63 kJ/mol) (in contrast to -1 to -4 kcal/mol or, -4 to -17 kJ/mol) for simple phosphoric esters like glucose-6-phosphate or alpha-glycerophosphates), thus being capable of driving energy-consuming reactions in living cells or reconstituted cell-free systems; adenosine 5'-triphosphate, with respect to the beta-and gamma-phosphates, is the best known and is regarded as the immediate energy source for most metabolic syntheses. The general types are acid anhydrides, phosphoric esters of enols, phosphamic acid (R-NH-PO3H2) derivatives, acyl thioesters (e.g., of coenzyme A), sulfonium compound's (R3-S+), and aminoacyl esters of ribosyl moieties.
See: high energy phosphates.
(05 Mar 2000)
high energy particle generating unit A machine capable of providing highly energised radiation for the purposes of radiotherapy treatment.
(16 Dec 1997)
high energy phosphate bond See: high energy phosphates.
(05 Mar 2000)
high energy phosphates Those phosphate's that, on hydrolysis, yield an unusually large amount of energy; e.g., nucleotide polyphosphates such as ATP, enol phosphate's such as phosphoenolpyruvate.
See: high energy compounds.
Synonym: energy-rich phosphates.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • high jinks
    ½Å³ª°Ô(Èïû¸Áû) ¶°µé±â
  • high jump
    ³ôÀ̶ٱâ
  • high life
    »ó·ù »çȸ(ÀÇ »ýȰ)
  • high liver
    »çÄ¡½º·¯¿î »ýȰÀ» ÇÏ´Â »ç¶÷;¹Ì½Ä°¡
  • high living
    ȣȭ½º·¯¿î »ýȰ 
  • high noon
    Çѳ·;Á¤¿À
  • high pillow
    °Å¹°;Áß¿ä Àι°
  • high pitch
    (³ëÁ¡ »óÀÎÀÇ)ÆÇ¸Å´ë
  • high place
    »ê²À´ë±âÀÇ ¿¹¹è Àå¼Ò;Áß¿äÇÑ ÁöÀ§;¿äÁ÷;°í°ü
  • high pockets
    Ű´Ù¸®
  • high point
    Áß´ëÇÑ ½ÃÁ¡;ÃÖ°íÀÇ ½Ã±â
  • high polymer
    °íºÐÀÚ(°Å´ëºÐÀÚ) ¹°Áú
  • high polymer chemistry
    °íºÐÀÚ(È­)ÇÐÀÇ;°­·ÂÇÑ;(±¤ÇÐ ±â±â°¡)¹èÀ²ÀÌ ³ôÀº;Á¤·ÂÀûÀÎ
  • high priest
    Á¦»çÀå;(¿¾ À¯´ë±³ÀÇ)´ëÁ¦»çÀå;°í½Â;(ÁÖÀÇ,¿îµ¿ÀÇ)ÁöµµÀÚ
  • high profile
    ¸íÈ®ÇÑ Åµµ(Á¤Ã¥);¼±¸íÇÑ ÀÔÀå
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á